🎄🌟 🎉 Wishing our readers a Merry Christmas and a Happy New Year filled with new possibilities! 🎄🌟 🎉

Monday, 23 December 2024


Aussie chemotherapy drug gets orphan designation

23 April 2015 | News | By BioSpectrum Bureau

Aussie chemotherapy drug gets orphan designation

Cantrixil is a chemotherapy drug for ovarian cancer

Cantrixil is a chemotherapy drug for ovarian cancer

Singappore: US Food and Drug Administration (FDA) has granted orphan drug designation to chemotherapy drug candidate Cantrixil for ovarian cancer developed by CanTx, a subsidiary joint venture of Australia's Novogen and Yale University.

Orphan Drug Designation is an important development for any experimental drug and has been instigated in a number of territories including the US, Europe and Australia to encourage the development of drugs for clinical indications that do not have a high incidence.

Mr Graham Kelly, CEO, Novogen and CanTx, said, "Receiving this designation is one more step in our objective of bringing Cantrixil to market as a drug that we hope will provide meaningful clinical benefit to patients with ovarian cancer and deliver that long-sought breakthrough for patients with a cancer that has shown only slight improvement in 5-year survival rates over the last 30 years.

"CanTx came out of a belief by Yale University and some long-term ovarian cancer researchers in the Yale Medical School that Cantrixil represented a potential breakthrough in the treatment of ovarian cancer," Mr Kelly added.

Cantrixil is on track to enter the clinic in Australia in late-2015/early-2016 in patients with the condition, malignant ascites, a terminal condition associated with cancers such as ovarian cancer and for which no effective long-term therapies exist.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account